Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria
- PMID: 30251929
- DOI: 10.1148/radiol.2018180628
Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria
Abstract
Purpose To evaluate the diagnostic performance of CT in the determination of pancreatic cancer resectability according to the National Comprehensive Cancer Network (NCCN) criteria to predict R0 resection. Materials and Methods Structured reports of pancreatic CT clinically prepared by board-certified abdominal radiologists from January 2014 to March 2017 were retrospectively reviewed to assess resectability (resectable, borderline resectable, or unresectable) according to NCCN criteria (version 1.2017) in 616 patients (369 men, 247 women; mean age, 63 years ± 10 [standard deviation]) with pancreatic cancer. Negative resection margin (R0) rates were assessed based on CT resectability status in patients who underwent upfront surgery. R0 resection-associated factors were identified by using logistic regression analysis. Results In 371 patients who underwent surgery, R0 resection rates were 73% (171 of 235), 55% (57 of 104), and 16% (five of 32) for resectable, borderline resectable, and unresectable disease, respectively (P < .001). At multivariable analysis, tumor diameter larger than 4 cm (P < .001) and abutment to the portomesenteric vein (P < .001) were significantly associated with margin-positive resection in patients with resectable disease at CT. R0 resection rates were 80% (123 of 154) for resectable disease without portomesenteric vein abutment, 59% (48 of 81) for resectable disease with portomesenteric vein abutment, 83% (57 of 69) for resectable disease 2 cm or smaller, and 29% (five of 17) for tumors larger than 4 cm. Conclusion CT resectability is used to stratify patients with pancreatic cancer according to the possibility of R0 resection. Larger tumor size and tumor abutment to the portomesenteric vein are associated with margin-positive resection in patients with resectable pancreatic cancer. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Fowler in this issue.
Comment in
-
CT Assessment of Pancreatic Cancer: What Are the Gaps in Predicting Surgical Outcomes?Radiology. 2018 Dec;289(3):719-720. doi: 10.1148/radiol.2018181912. Epub 2018 Sep 25. Radiology. 2018. PMID: 30251932 No abstract available.
Similar articles
-
Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion.Eur Radiol. 2021 Sep;31(9):6889-6897. doi: 10.1007/s00330-021-07847-4. Epub 2021 Mar 19. Eur Radiol. 2021. PMID: 33740095
-
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.Eur Radiol. 2021 Feb;31(2):813-823. doi: 10.1007/s00330-020-07188-8. Epub 2020 Aug 26. Eur Radiol. 2021. PMID: 32845389
-
Predicting resection margin status of pancreatic neuroendocrine tumors on CT: performance of NCCN resectability criteria.Br J Radiol. 2023 Dec;96(1152):20230503. doi: 10.1259/bjr.20230503. Epub 2023 Oct 24. Br J Radiol. 2023. PMID: 37750830 Free PMC article.
-
Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.Dan Med J. 2012 Dec;59(12):B4568. Dan Med J. 2012. PMID: 23290296 Review.
-
CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.Eur Radiol. 2021 May;31(5):3383-3393. doi: 10.1007/s00330-020-07433-0. Epub 2020 Oct 30. Eur Radiol. 2021. PMID: 33123793
Cited by
-
Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography.J Clin Med. 2021 Mar 10;10(6):1151. doi: 10.3390/jcm10061151. J Clin Med. 2021. PMID: 33801810 Free PMC article. Review.
-
Pretherapeutic Assessment of Pancreatic Cancer: Comparison of FDG PET/CT Plus Delayed PET/MR and Contrast-Enhanced CT/MR.Front Oncol. 2022 Jan 14;11:790462. doi: 10.3389/fonc.2021.790462. eCollection 2021. Front Oncol. 2022. PMID: 35096590 Free PMC article.
-
CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study.Radiology. 2021 Dec;301(3):610-622. doi: 10.1148/radiol.2021210699. Epub 2021 Sep 7. Radiology. 2021. PMID: 34491129 Free PMC article.
-
Comparison of the efficacy of FITC-conjugated dextran, PEG, and HA as intraoperative navigation materials in pancreatic cancer.RSC Adv. 2025 Aug 19;15(36):29300-29310. doi: 10.1039/d5ra02236c. eCollection 2025 Aug 18. RSC Adv. 2025. PMID: 40860116 Free PMC article.
-
A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center retrospective study.Eur Radiol. 2025 May 2. doi: 10.1007/s00330-025-11632-y. Online ahead of print. Eur Radiol. 2025. PMID: 40314786
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical